CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 11 enrolled
Drug / intervention
Carotuximab (TRC105) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03181308
NCT03181308Phase 1Completed
CompareCT.gov

A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer

Tracon Pharmaceuticals Inc.·interventional·Posted Jun 8, 2017·Updated Jun 24, 2020

In Brief

A Phase 1 clinical trial evaluating Carotuximab (TRC105) and OPDIVO for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 11 participants across 2 sites.

Detailed Summary

This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or PD-1/PD-L1 checkpoint inhibition, as a single agent or with chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJun 8, 2017
Enrollment StartNov 9, 2017
Primary CompletionJul 22, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.1 years ago

Interventions

Carotuximab (TRC105)drug

Anti Endoglin Antibody

OPDIVOdrug

Programmed Death Receptor-1